fool.comAUG 231 min read$CAH

The CIO of Cardinal Health Parted With 11,650 Shares. Here's Whether It Matters for Long-Term Investors

Cardinal Health, Inc. (CAH) CIO Michelle D. Greene sold 11,650 shares on August 18, according to an SEC filing. The shares were sold at prices ranging from $234.07 to $237.32, with a weighted average of $235.72. Post-sale, Greene retains 10,330 shares. Cardinal Health has a market cap of $55.0 billion and generated $254.2 billion in TTM revenue, with net income of $1.7 billion.

Original reporting

fool.com

Published Aug 23, 2026, 12:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 12:19 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

The CIO of Cardinal Health Parted With 11,650 Shares. Here's Whether It Matters for Long-Term Investors — source image — Source · fool.com

Decision brief

The 30-second read

$CAHNeutralLow

Why it matters

The filing provides fresh data on insider holdings but is unlikely to drive price action.

Market read

Primary insider sale with modest size; low trading relevance.

What to watch

Potential upcoming strategic initiatives not reflected in the filing.

Relevance 4/10Novelty 4/10Timing: post‑market Aug 18

Background

Cardinal Health is a $55B global healthcare services provider.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHNeutralMedium confidence

Context

CIO Michelle Greene sold 11,650 shares of Cardinal Health on Aug 18, disclosed via SEC Form 4.

Expected impact

Potential slight downward pressure, unlikely to move price materially.

Evidence & confidence

Sale amount (~$2.7M) is small for a $55B company; market may view as routine.

Market effects

Sector

Minimal impact on healthcare distribution sector.

Regional

No significant regional effect.

Global

Limited relevance globally.

Counterpoint

What could challenge this read

Insider sale could be unrelated to fundamentals; investors may ignore.

Key entities

Executive
Michelle D. Greene
Chief Information Officer of Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min